ATE514716T1 - Fragmente toxin-bezogener antikörper, mit antimikrobieller und antiviraler aktivität - Google Patents

Fragmente toxin-bezogener antikörper, mit antimikrobieller und antiviraler aktivität

Info

Publication number
ATE514716T1
ATE514716T1 AT03727860T AT03727860T ATE514716T1 AT E514716 T1 ATE514716 T1 AT E514716T1 AT 03727860 T AT03727860 T AT 03727860T AT 03727860 T AT03727860 T AT 03727860T AT E514716 T1 ATE514716 T1 AT E514716T1
Authority
AT
Austria
Prior art keywords
fragments
antiviral activity
toxin
antimicrobial
microbicidal
Prior art date
Application number
AT03727860T
Other languages
English (en)
Inventor
Luciano Polonelli
Antonio Cassone
Paolo Neri
Luisa Bracci
Luisa Lozzi
Original Assignee
Univ Siena
Luciano Polonelli
Ist Superiore Sanita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Siena, Luciano Polonelli, Ist Superiore Sanita filed Critical Univ Siena
Application granted granted Critical
Publication of ATE514716T1 publication Critical patent/ATE514716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT03727860T 2002-05-10 2003-05-09 Fragmente toxin-bezogener antikörper, mit antimikrobieller und antiviraler aktivität ATE514716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210783.7A GB0210783D0 (en) 2002-05-10 2002-05-10 Anti-microbial polypeptides
PCT/IB2003/002348 WO2003095493A2 (en) 2002-05-10 2003-05-09 Toxin-related antibodies with antimicrobial and antiviral activity

Publications (1)

Publication Number Publication Date
ATE514716T1 true ATE514716T1 (de) 2011-07-15

Family

ID=9936462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03727860T ATE514716T1 (de) 2002-05-10 2003-05-09 Fragmente toxin-bezogener antikörper, mit antimikrobieller und antiviraler aktivität

Country Status (12)

Country Link
US (1) US7722876B2 (de)
EP (1) EP1504036B1 (de)
JP (1) JP4405912B2 (de)
AT (1) ATE514716T1 (de)
AU (1) AU2003233108A1 (de)
BR (1) BR0309921A (de)
CA (1) CA2484704A1 (de)
CO (1) CO7220324A2 (de)
DK (1) DK1504036T3 (de)
GB (1) GB0210783D0 (de)
NZ (1) NZ536957A (de)
WO (1) WO2003095493A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006093071A1 (ja) * 2005-02-28 2008-08-07 株式会社ジーンケア研究所 βグルカン合成酵素を有する真菌に対して抗真菌活性を有する抗イディオタイプ抗体、およびその利用
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
WO2011060393A1 (en) * 2009-11-16 2011-05-19 Rasna Therapeutics Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore
EP3604339B1 (de) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutische antikörper gegen das ror-1-protein und verfahren zur verwendung davon
WO2013008171A1 (en) * 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
WO2020257625A1 (en) * 2019-06-21 2020-12-24 Rowley Paul A Compositions and methods for inhibiting yeast infections
US20220111018A1 (en) * 2020-06-19 2022-04-14 University Of Idaho Compositions and methods for inhibiting yeast infections
CN111848740B (zh) * 2020-08-04 2023-03-24 南京市妇幼保健院 一种阴道分泌源性多肽及其在抑制白色念珠菌感染中的应用
EP4147716A1 (de) * 2021-09-10 2023-03-15 Samatva Research Corporation In einer matrix immobilisierte anti-virus komponente

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
WO1998008090A1 (en) 1995-06-06 1998-02-26 Epigen, Inc. Anti-idiotypic antibodies to an epiglycanin
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
DK1069185T3 (da) * 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
AU1157100A (en) * 1998-10-29 2000-05-22 Connex Gmbh Detection of acid-resistant micro-organisms in a stool
HUP0301208A2 (hu) * 1999-02-12 2003-08-28 Genetics Institute, Llc B7-molekulákkal reagáló humanizált immunglobulin és az ezekkel végzett kezelési eljárások
WO2000079275A1 (en) 1999-06-17 2000-12-28 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for diseases with participation of macrocytes/macrophages
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
EP1130032A1 (de) * 2000-02-28 2001-09-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Einzelkette-Antikörper die den menschlichen vaskulären endothelialen Wachstumsfaktorrezeptor-2 (VEGFR-2/KDR) erkennen
DE10019967A1 (de) 2000-04-20 2001-10-25 Fenning Biomed Gmbh Dr Antikörper gegen natives gp96, deren Herstellung und Verwendung
CA2412494C (en) * 2000-06-22 2012-10-23 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies

Also Published As

Publication number Publication date
EP1504036A2 (de) 2005-02-09
JP4405912B2 (ja) 2010-01-27
AU2003233108A1 (en) 2003-11-11
US20060280750A1 (en) 2006-12-14
GB0210783D0 (en) 2002-06-19
CO7220324A2 (es) 2015-03-20
EP1504036B1 (de) 2011-06-29
US7722876B2 (en) 2010-05-25
WO2003095493A3 (en) 2004-06-03
BR0309921A (pt) 2005-02-09
JP2006506959A (ja) 2006-03-02
CA2484704A1 (en) 2003-11-20
DK1504036T3 (da) 2011-10-24
WO2003095493A2 (en) 2003-11-20
NZ536957A (en) 2006-07-28

Similar Documents

Publication Publication Date Title
DE69435105D1 (de) Derivate therapeutischer Peptide
ATE368053T1 (de) Antimikrobielle peptide
ATE286740T1 (de) Zyklische peptide mit breitspektrum antimikrobieller aktivität
EA200100447A1 (ru) Гибридные белки на основе бета-интерферона и их применение
WO2002010195A3 (en) Modified peptides with increased potency
DE69613137D1 (de) Zyklische peptidanaloga von somatostatin
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
ATE514716T1 (de) Fragmente toxin-bezogener antikörper, mit antimikrobieller und antiviraler aktivität
ES2172044T3 (es) Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina.
GB9606040D0 (en) Active peptide
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
DE68917837D1 (de) Peptid-Verbindungen.
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
DK1012175T3 (da) Peptid med affinitet til koagulationsfaktor VIII
DE60236330D1 (de) Biologisch aktive Peptide
ATE245168T1 (de) Peptide, die anti-zellanhaftungsaktivität aufweisen
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
SE9700301D0 (sv) New compound
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
RU2002113819A (ru) Пептид, обладающий регулирующей биологической активностью на белковый синтез в гепатоцитах
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
WO1999060117A3 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties